Come listen to MedSIR Founders Maria Campos, Dr. Javier Cortés, and Dr. Antonio Llombart speak about the MedSIR concept and how we are currently optimizing clinical research in Oncology.

Don’t miss Dr. José Perez, Breast Cancer Specialist, speaking about the role MedSIR plays in his everyday research.

WELCOME TO MEDSIR!

Here we are dedicated to the design and management of clinical trials involving some of the most important current drugs in Oncology such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, radium-223 and many more and we’d be thrilled to help you transform your idea into a high-level strategic clinical trial by applying our simple method:

First off, you confidentially send us your idea… a few lines, or a short synopsis is all we need.

Then, your idea will be reviewed by our network of cancer experts while our statistician develops a realistic scenario for the study to be carried out.

Lastly, we confidentially present the proposal to a potential funder, negotiating a win-win situation that satisfies all parties.

If the project is approved, you will join our team and play a lead role in all study aspects all the way through to the publication of study results. Meanwhile, our clinical operations team professionally manages the trial, respecting ISO 9001-certified quality, while placing a major focus on accrual timelines: The faster we move, the quicker we can produce results and improve patient lives.


50% Global Recruitment in BARBICAN Study

In BARBICAN study, 50% of the patients were randomized successfully throughout Europe. Currently, the overall recruitment of the trial is 73 patients. The patient number 73 was randomized at the Vall d’Hebrón...
READ MORE...
INTERVIEW: Dr. Cinta Albacar, Hospital Universitari Sant Joan de Reus

We start a New Year in a spirit of hope for the many breast cancer patients and their families. Today, we are very happy to share a brief interview with Dr. Cinta Albacar, from...
READ MORE...
First results of the transFAL study in SABCS 2019

In precision medicine, the study of the molecular profile of the disease and how it is modified by the different treatments is paramount. Thus, MedSIR trials are always designed with a translational objective in mind...
READ MORE...
PHENOMENAL Study reach a New Milestone!

This last September (2019), the 23rd patient in the Phenomenal Study was included in the trial. We have reached a new milestone, the Stage I have recruited 23 evaluable patients. An interim analysis...
READ MORE...
REVERT Study Poster Presentation at SABCS 2019

REVERT study (design, background, primary, a secondary endpoint, trial enrollment) has been scheduled for presentation in a Poster Session at SABCS 2019 on San Antonio (Texas, USA)...
READ MORE...
The Beginning of the LUZERN Study

Last 11th November 2019, it was submitted the LUZERN study to AEMPS and CEIm with the participation of 10 different sites in Spain. Overall, we expect to recruit a total of 23 patients. Sites activation is...
READ MORE...